Protein Summary
May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling. The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expresse ...more
- ENST00000318424
- ENSP00000320058
- ENSG00000103855
- ENST00000318443
- ENSP00000320084
- ENST00000561213
- ENSP00000452736
- ENST00000564751
- ENSP00000454940
- B7H3
- B7H3
- B7-H3
- B7RP-2
- 4Ig-B7-H3
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 1 | ||
biological process | 0.93 | ||
protein domain | 0.85 | ||
microRNA | 0.73 | ||
biological term | 0.64 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 957.94 (req: < 5)
Gene RIFs: 201 (req: <= 3)
Antibodies: 799 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 957.94 (req: >= 5)
Gene RIFs: 201 (req: > 3)
Antibodies: 799 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0